Home Dice DICE Therapeutics (NASDAQ: DICE) rating downgraded to sell at Zacks Investment Research

DICE Therapeutics (NASDAQ: DICE) rating downgraded to sell at Zacks Investment Research

0

DICE Therapeutics (NASDAQ: DICE) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday, Zacks.com reports.

According to Zacks, “DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform creates a pipeline of new oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, California. . “

A number of other research analysts have also recently published reports on DICE. SVB Leerink assumed coverage of DICE Therapeutics shares in a report released on Monday, October 11. They set an “outperformance” rating and a price target of $ 46.00 for the company. Bank of America began covering shares of DICE Therapeutics in a research note on Monday, October 11. They issued a “buy” note and a target price of $ 41.00 on the stock. Finally, Evercore ISI began covering shares of DICE Therapeutics in a research note on Monday, October 11. They issued an “outperformance” rating and a target price of $ 60.00 on the stock.

NASDAQ: DICE shares traded down $ 1.52 in Friday’s session, reaching $ 26.58. 254,979 shares of the company were traded, for an average volume of 196,201. DICE Therapeutics has a one-year low at $ 23.16 and a one-year high at $ 40.50. The company’s 50-day moving average is $ 31.15.

DICE Therapeutics (NASDAQ: DICE) last released its quarterly results on Friday, November 12. The company reported ($ 2.30) EPS for the quarter, missing the consensus estimate of ($ 0.53) of ($ 1.77). On average, sell-side analysts predict that DICE Therapeutics will post an EPS of -2.9 for the current year.

(A d)

“Options Basics” is the new comprehensive toolbelt for traders, full of clear English instructions, real-life examples and simple, reliable tactics to get you started!

A number of hedge funds and other institutional investors have recently bought and sold shares in the company. ArrowMark Colorado Holdings LLC purchased a new stake in DICE Therapeutics during the third quarter valued at $ 13,442,000. Suvretta Capital Management LLC acquired a new stake in DICE Therapeutics during the third quarter for a value of $ 13,428,000. Janus Henderson Group PLC purchased a new stake in DICE Therapeutics during the third quarter valued at $ 58,627,000. Millennium Management LLC purchased a new stake in DICE Therapeutics during the third quarter valued at $ 12,005,000. Finally, Point72 Hong Kong Ltd acquired a new stake in DICE Therapeutics during the third quarter for an amount of $ 203,000. 32.06% of the shares are currently held by hedge funds and other institutional investors.

DICE Therapeutics Company Profile

DICE Therapeutics Inc is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of new oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc is based in SOUTH SAN FRANCISCO, California.

Featured article: Earnings per share

Get a Free Copy of Zacks’ DICE Therapeutics (DICE) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in DICE Therapeutics now?

Before you consider DICE Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and DICE Therapeutics was not on the list.

While DICE Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bids.

See the 5 actions here